![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GUCA1B |
Gene summary for GUCA1B |
![]() |
Gene information | Species | Human | Gene symbol | GUCA1B | Gene ID | 2979 |
Gene name | guanylate cyclase activator 1B | |
Gene Alias | GCAP 2 | |
Cytomap | 6p21.1 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q7Z3V9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2979 | GUCA1B | HCC1 | Human | Liver | HCC | 9.98e-03 | 1.99e+00 | 0.5336 |
2979 | GUCA1B | HCC2 | Human | Liver | HCC | 3.10e-15 | 1.14e+00 | 0.5341 |
2979 | GUCA1B | HCC5 | Human | Liver | HCC | 1.50e-16 | 1.31e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
GO:007252122 | Liver | HCC | purine-containing compound metabolic process | 250/7958 | 416/18723 | 2.26e-13 | 1.24e-11 | 250 |
GO:000616322 | Liver | HCC | purine nucleotide metabolic process | 236/7958 | 396/18723 | 3.59e-12 | 1.62e-10 | 236 |
GO:006201222 | Liver | HCC | regulation of small molecule metabolic process | 190/7958 | 334/18723 | 6.77e-08 | 1.40e-06 | 190 |
GO:000916512 | Liver | HCC | nucleotide biosynthetic process | 150/7958 | 254/18723 | 6.79e-08 | 1.40e-06 | 150 |
GO:190129312 | Liver | HCC | nucleoside phosphate biosynthetic process | 151/7958 | 256/18723 | 6.84e-08 | 1.41e-06 | 151 |
GO:007252212 | Liver | HCC | purine-containing compound biosynthetic process | 114/7958 | 200/18723 | 2.36e-05 | 2.49e-04 | 114 |
GO:000616412 | Liver | HCC | purine nucleotide biosynthetic process | 107/7958 | 191/18723 | 1.08e-04 | 9.22e-04 | 107 |
GO:005087822 | Liver | HCC | regulation of body fluid levels | 191/7958 | 379/18723 | 1.06e-03 | 6.11e-03 | 191 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GUCA1B | SNV | Missense_Mutation | novel | c.288N>C | p.Trp96Cys | p.W96C | Q9UMX6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GUCA1B | SNV | Missense_Mutation | c.160N>T | p.Ala54Ser | p.A54S | Q9UMX6 | protein_coding | deleterious(0.03) | possibly_damaging(0.903) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
GUCA1B | SNV | Missense_Mutation | rs771976584 | c.584G>A | p.Arg195Gln | p.R195Q | Q9UMX6 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GUCA1B | SNV | Missense_Mutation | rs750812813 | c.332G>A | p.Arg111His | p.R111H | Q9UMX6 | protein_coding | tolerated(0.07) | benign(0.079) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GUCA1B | SNV | Missense_Mutation | novel | c.78N>C | p.Lys26Asn | p.K26N | Q9UMX6 | protein_coding | deleterious(0.01) | benign(0.442) | TCGA-VS-A950-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
GUCA1B | SNV | Missense_Mutation | novel | c.581N>T | p.Arg194Ile | p.R194I | Q9UMX6 | protein_coding | deleterious(0.01) | possibly_damaging(0.642) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GUCA1B | SNV | Missense_Mutation | rs750812813 | c.332G>A | p.Arg111His | p.R111H | Q9UMX6 | protein_coding | tolerated(0.07) | benign(0.079) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GUCA1B | SNV | Missense_Mutation | rs755162612 | c.514N>T | p.Arg172Trp | p.R172W | Q9UMX6 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR |
GUCA1B | SNV | Missense_Mutation | rs555181489 | c.29N>T | p.Ala10Val | p.A10V | Q9UMX6 | protein_coding | tolerated(0.19) | benign(0) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
GUCA1B | SNV | Missense_Mutation | novel | c.29N>G | p.Ala10Gly | p.A10G | Q9UMX6 | protein_coding | tolerated(0.46) | benign(0) | TCGA-A5-A0R9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |